195 related articles for article (PubMed ID: 35303106)
21. Endocrine-related adverse events associated with immune-checkpoint inhibitors in patients with melanoma.
Kassi E; Angelousi A; Asonitis N; Diamantopoulos P; Anastasopoulou A; Papaxoinis G; Kokkinos M; Giovanopoulos I; Kyriakakis G; Petychaki F; Savelli A; Benopoulou O; Gogas H
Cancer Med; 2019 Nov; 8(15):6585-6594. PubMed ID: 31518074
[TBL] [Abstract][Full Text] [Related]
22. American Association of Clinical Endocrinology Disease State Clinical Review: Evaluation and Management of Immune Checkpoint Inhibitor-Mediated Endocrinopathies: A Practical Case-Based Clinical Approach.
Yuen KCJ; Samson SL; Bancos I; Gosmanov AR; Jasim S; Fecher LA; Weber JS
Endocr Pract; 2022 Jul; 28(7):719-731. PubMed ID: 35477029
[TBL] [Abstract][Full Text] [Related]
23. Autoantibody profiles in patients with immune checkpoint inhibitor-induced neurological immune related adverse events.
Müller-Jensen L; Knauss S; Ginesta Roque L; Schinke C; Maierhof SK; Bartels F; Finke C; Rentzsch K; Ulrich C; Mohr R; Stenzel W; Endres M; Boehmerle W; Huehnchen P
Front Immunol; 2023; 14():1108116. PubMed ID: 36845122
[TBL] [Abstract][Full Text] [Related]
24. The Uncharted Landscape of Rare Endocrine Immune-Related Adverse Events.
Mytareli C; Ziogas DC; Karampela A; Papalexis P; Siampanopoulou V; Lafioniatis A; Benopoulou O; Gogas H; Angelousi A
Cancers (Basel); 2023 Mar; 15(7):. PubMed ID: 37046677
[TBL] [Abstract][Full Text] [Related]
25. Encephalitis Induced by Immune Checkpoint Inhibitors: A Systematic Review.
Velasco R; Villagrán M; Jové M; Simó M; Vilariño N; Alemany M; Palmero R; Martínez-Villacampa MM; Nadal E; Bruna J
JAMA Neurol; 2021 Jul; 78(7):864-873. PubMed ID: 33720308
[TBL] [Abstract][Full Text] [Related]
26. Association of Antithyroid Antibodies in Checkpoint Inhibitor-Associated Thyroid Immune-Related Adverse Events.
Muir CA; Wood CCG; Clifton-Bligh RJ; Long GV; Scolyer RA; Carlino MS; Menzies AM; Tsang VHM
J Clin Endocrinol Metab; 2022 Apr; 107(5):e1843-e1849. PubMed ID: 35104870
[TBL] [Abstract][Full Text] [Related]
27. Divergent prognostic effects of pre-existing and treatment-emergent thyroid dysfunction in patients treated with immune checkpoint inhibitors.
von Itzstein MS; Gonugunta AS; Wang Y; Sheffield T; Lu R; Ali S; Fattah FJ; Xie D; Cai J; Xie Y; Gerber DE
Cancer Immunol Immunother; 2022 Sep; 71(9):2169-2181. PubMed ID: 35072744
[TBL] [Abstract][Full Text] [Related]
28. Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis.
Barroso-Sousa R; Barry WT; Garrido-Castro AC; Hodi FS; Min L; Krop IE; Tolaney SM
JAMA Oncol; 2018 Feb; 4(2):173-182. PubMed ID: 28973656
[TBL] [Abstract][Full Text] [Related]
29. Anti-pituitary antibodies and susceptible human leukocyte antigen alleles as predictive biomarkers for pituitary dysfunction induced by immune checkpoint inhibitors.
Kobayashi T; Iwama S; Sugiyama D; Yasuda Y; Okuji T; Ito M; Ito S; Sugiyama M; Onoue T; Takagi H; Hagiwara D; Ito Y; Suga H; Banno R; Nishikawa H; Arima H
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34011534
[TBL] [Abstract][Full Text] [Related]
30. Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer.
Godwin JL; Jaggi S; Sirisena I; Sharda P; Rao AD; Mehra R; Veloski C
J Immunother Cancer; 2017; 5():40. PubMed ID: 28515940
[TBL] [Abstract][Full Text] [Related]
31. Autoimmune polyendocrine syndrome induced by immune checkpoint inhibitors: a systematic review.
Zhao Z; Wang X; Bao XQ; Ning J; Shang M; Zhang D
Cancer Immunol Immunother; 2021 Jun; 70(6):1527-1540. PubMed ID: 33200250
[TBL] [Abstract][Full Text] [Related]
32. Coexistence of Immune Checkpoint Inhibitor-Induced Autoimmune Diabetes and Pancreatitis.
Zhang AL; Wang F; Chang LS; McDonnell ME; Min L
Front Endocrinol (Lausanne); 2021; 12():620522. PubMed ID: 33927691
[TBL] [Abstract][Full Text] [Related]
33. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS
Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117
[TBL] [Abstract][Full Text] [Related]
34. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
35. Endocrine Adverse Events Caused by Different Types and Different Doses of Immune Checkpoint Inhibitors in the Treatment of Solid Tumors: A Meta-Analysis and Systematic Review.
Yang Y; Liu J; Yang K; Ma Y; Fu S; Tang X; Wang Y; Zhou L
J Clin Pharmacol; 2021 Mar; 61(3):282-297. PubMed ID: 33345342
[TBL] [Abstract][Full Text] [Related]
36. Endocrine Adverse Events Related To Immune Checkpoint Inhibitor Treatment: Relationship Between Antibodies and Severity of Thyroid Dysfunction.
Miguélez González M; Galdón Sanz-Pastor A; Áñez Gómez R; Brox Torrecilla N; Muñoz Moreno D; González Fernández L; Maricel Rivas A; López Guerra A; Álvarez R; Arranz JÁ; Márquez Rodas I; Escudero V; Sanjurjo M; Martín Vallejo J; Martín M; González Albarrán O
Endocr Metab Immune Disord Drug Targets; 2024 Feb; ():. PubMed ID: 38362680
[TBL] [Abstract][Full Text] [Related]
37. Approach to the Patient With Immune Checkpoint Inhibitor-Associated Endocrine Dysfunction.
Wright JJ; Johnson DB
J Clin Endocrinol Metab; 2023 May; 108(6):1514-1525. PubMed ID: 36481794
[TBL] [Abstract][Full Text] [Related]
38. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
39. Emergency Presentations of Immune Checkpoint Inhibitor-Related Endocrinopathies.
Knight T; Cooksley T
J Emerg Med; 2021 Aug; 61(2):140-146. PubMed ID: 33795170
[TBL] [Abstract][Full Text] [Related]
40. Thyroid Toxicity Following Immune Checkpoint Inhibitor Treatment in Advanced Cancer.
Muir CA; Menzies AM; Clifton-Bligh R; Tsang VHM
Thyroid; 2020 Oct; 30(10):1458-1469. PubMed ID: 32264785
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
